Market Introduction
Fungal systemic infections are common in patients with weakened immune system, including immunosuppression and acquired immunodeficiency syndrome (AIDS) patients. Systemic signs consolidate apnea, guaiac-positive stools, abdominal distension, hyperglycemia, leukemoid reaction, hypotension, and others. The treatment of systemic candidiasis and aspergillos need parenteral antifungal therapy and this condition is associated with high mortality rate. Furthermore, this infection may result in permanent neurodevelopmental deficits in long-term survivors.
Market Overview and Dynamics
The Asia Pacific systemic aspergillosis and systemic candidasis market is projected to reach US$ 2,030.54 million by 2027 from US$ 1,437.77 million in 2019; it is estimated to grow with a CAGR of 4.5% from 2020 to 2027. The growth of the Asia Pacific systemic aspergillosis and systemic candidasis market is attributed to the rise in prevalence of fungal diseases, rising hospital acquired fungal infection. However, increasing resistance to antifungal drugs, side effects of antifungal drugs limits the growth of market in this region. Countries in Asia Pacific are expecting to witness huge challenge due to growing COVID-19. Due to outbreak of disease, healthcare industries has been affected badly and many business related activities such as product launches and product promotion conferences has been postponed, leading to restraining the growth of the market.
Key Market Segments
Based on type, the Asia Pacific systemic aspergillosis and systemic candidasis market is segmented into voriconazole, liposomal, amphotericin b, systemic oral azoles, topical, antifungal agents, and others. In 2019, the systemic oral azoles segment held a larger share of the market. And is expected to grow at a faster rate during the forecast period.
Major Sources and Companies Listed
A few major primary and secondary sources referred to while preparing the Asia Pacific systemic aspergillosis and systemic candidasis Market report are World Health Organization, Ministry of Health and Prevention, and Ministry of Health and Family Welfare.
Novartis AG, Sanofi, Pfizer Inc., Merck & Co., Inc., Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plc., Abbott, Cipla Inc., Enzon Pharmaceuticals, Inc,.
Reasons to buy the report
ASIA PACIFIC SYSTEMIC ASPERGILLOSIS AND SYSTEMIC CANDIDASIS MARKET SEGMENTATION
By Country
Company Profiles